Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus receptor-related 2 (PVRL2), also known as Nectin-2 or CD112, is a transmembrane glycoprotein belonging to the Nectin family and the immunoglobulin superfamily. It is a key component of adherens junctions, where it mediates cell-cell adhesion through homophilic and heterophilic interactions. In addition to its structural role, PVRL2 serves as a critical immune checkpoint ligand that is frequently overexpressed in various cancers, including ovarian, endometrial, and lung carcinomas. It modulates immune cell activity by binding to several receptors on T cells and natural killer (NK) cells: the inhibitory receptors PVRIG (CD112R) and TIGIT, and the activating receptor DNAM-1 (CD226). The interaction between PVRL2 and PVRIG is a potent immunosuppressive pathway that tumors exploit to evade immune surveillance. Consequently, PVRL2 is a significant therapeutic target in oncology, with drug development efforts focusing on blocking its interaction with inhibitory receptors. While direct anti-PVRL2 antibodies are primarily in preclinical stages, agents like COM701 (an anti-PVRIG antibody) are being evaluated in clinical trials to disrupt this axis and enhance anti-tumor immunity.
Immune checkpoint inhibition by blocking the interaction between PVRL2 and its inhibitory receptors PVRIG or TIGIT to restore T cell and NK cell anti-tumor activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus receptor-related 2 (Nectin-2) (PVRL2).